Clinical trials: 5-FU
Colorectal Cancer Stage IV
Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
The investigators hypothesize that intermittent first-line Panitumumab plus FOLFIRI is effective in first line as the same regimen given continuously, resulting in a Time to Treatment Failure (TTF) not inferior to that obtained…
- Trial name
- IMPROVE-2 (NCT06509126)
- Testing
- Panitumumab, Irinotecan, 5-fluorouracil
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- National Cancer Institute, Naples
Chemotherapy, Colorectal Cancer
Effect of Losartan on the Incidence and Severity of Chemotherapy-Induced Mucositis in Gastrointestinal Cancer Patients
Mucositis is a common and clinically significant side effect of both anticancer chemotherapy and radiation therapy that can affect any portion of the gastrointestinal tract.
- Conditions
- Chemotherapy, Colorectal Cancer, Intestinal Mucositis, Oral Mucositis
- Trial name
- NCT05871333
- Testing
- Losartan 50mg Tab
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Ain Shams University
Pancreatic Cancer
A Phase II Study of Combine Modality Therapy in Locally Advanced Pancreatic Cancer
Induction chemotherapy will be administered every 2 weeks for 6 cycles (about 3 months). Patients who have radiological evidence of progressive disease will be shifted to salvage chemotherapy.
- Trial name
- NCT00149578
- Testing
- Gemcitabine Oxaliplatin 5FU and Leucovorin
- Where
- 2 sites in Taiwan
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Health Research Institutes, Taiwan
Esophageal Cancer
Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using 18FDG-PET/CT for Unresectable Thoracic Esophageal Cancer
Most local failures after definitive chemoradiation for unresectable esophageal cancer occur in the gross tumor volume (GTV). And the metabolic active areas post-treatment were located in the high FDG uptake areas prior to the…
- Trial name
- NCT01843049
- Testing
- Radiotherapy, Chemotherapy (5-FU+DDP)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Progression-Free Survival
Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy
To investigate progression-free survival (PFS) in patients with metastatic colorectal cancer treated with chemotherapy FOLFIRI monotherapy or chemotherapy FOLFIRI combined with Metformin
- Trial name
- NCT06826092
- Testing
- Metformin Pill, FOLFIRI plus target therapy only
- Where
- Taiwan
- Volunteers
- 110 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Hepatitis C, Chronic
Neurocognitive Performance and Emotional State in HCV Patients With IFN-free Antiviral Therapy
The present study evaluates neurocognitive performance as well as measures of mood, quality of life, and fatigue in patients with chronic hepatitis C infection.
- Trial name
- IFNfreeCOG (NCT02469012)
- Testing
- Combination #1, Combination #2, Combination #3
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University of Wuerzburg
Pancreatic Cancer
A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer
The primary purpose of this study is to assess the safety and effectiveness of TNFerade™ Biologic when administered concurrently with 5-FU and radiation therapy as first-line treatment of unresectable locally advanced pancreatic…
- Trial name
- NCT00051467
- Testing
- TNFerade
- Where
- 25 sites in United States
- Sponsor
- GenVec
Colorectal Cancer
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00039611
- Testing
- FOLFOX regimen, fluorouracil, leucovorin calcium
- Where
- 19 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Colon Cancer
Adjuvant Chemotherapy In Elderly With Colon Cancer Stage III
This is a phase 2, randomized study where the aim of the study is to investigate the tolerance of adjuvant chemotherapy, measured by functional decline, after surgery for colon cancer stage III in elderly patients.
- Trial name
- ACE (NCT02978612)
- Testing
- Capecitabine
- Where
- Norway
- Volunteers
- 170 people
- Sponsor
- Oslo University Hospital
Hepatocellular Carcinoma, Portal Vein Tumor Thrombus
Comprehensive Treatment for Different Types of Tumor Thrombi in the Portal Vein for Hepatocellular Carcinoma Patients
This study is working to evaluate the surgical comprehensive treatment for different types of tumor thrombi in the portal vein for hepatocellular carcinoma patients, to establish a standardized, unified, effective therapeutic…
- Trial name
- NCT00849264
- Testing
- chemotherapy with endostar, treatment with CBP and 5-FU, treatment with endostar, CBP and 5-FU
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Unspecified Adult Solid Tumor, Protocol Specific
Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and best dose of alvocidib when given together with oxaliplatin, fluorouracil, and leucovorin calcium in treating patients with advanced solid tumors.
- Trial name
- NCT00080990
- Testing
- alvocidib, fluorouracil, oxaliplatin
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Urothelial Carcinoma, Bladder Cancer
Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC
This is a single-armed, multicenter, non-blinded phase 2 study to assess efficacy of induction ipilimumab + nivolumab followed by chemoradiation to spare the bladder in urothelial bladder cancer.
- Trial name
- Indi-Blade (NCT05200988)
- Testing
- Ipilimumab + nivolumab
- Where
- 3 sites in Netherlands
- Volunteers
- 50 people
- Sponsor
- The Netherlands Cancer Institute
Oncology
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
This is an open-label, multi-center, multi-national, non-randomized rollover study designed to allow continued access to napabucasin for patients who have participated in a Boston Biomedical-sponsored study and are being treated…
- Trial name
- NCT04299880
- Testing
- Napabucasin, Nab-paclitaxel, Gemcitabine
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 7 people
- Sponsor
- Sumitomo Pharma America, Inc.
Colorectal Neoplasms
FOLFOXIRI-based HAIC Combined With Fuquintinib as Late-line Treatment in Patients With CRLM：A Phase 2 Single-Arm Clinical Trial
This study was a phase 2, single-arm, single-center clinical trial in which previously treated patients with unresectable colorectal cancer liver metastases.
- Trial name
- HAIC，CRLM (NCT07024537)
- Testing
- FOLFOXIRI-based HAIC+Fuquinitinib
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Meng Qiu
Toxicity Due to Chemotherapy
Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination
The purpose of this study is to provide emergency treatment of adult and pediatric patients: Following a fluorouracil or capecitabine overdose regardless of the presence of symptoms or Who exhibit early-onset, severe or…
- Trial name
- NCT01432301
- Testing
- uridine triacetate
- Sponsor
- Wellstat Therapeutics
Metastatic Pancreatic Cancer
Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients
The aim of this study is to evaluate the efficacy of sequential treatment (Gabrinox) comprising Gembrax regimen (Gemcitabine -Abraxane) followed by the Folfirinox regimen (5FU, Oxaliplatin and Irinotecan) compared to folfirinox…
- Trial name
- GABRINOX2 (NCT05065801)
- Testing
- GEMBRAX/FOLFIRINOX Arm A, FOLFIRINOX Arm B
- Where
- 8 sites in France
- Volunteers
- 162 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Uterine Neoplasms
Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer
Primary: To assess the overall response rate of oxaliplatin in patients with bidimensionally measurable disease at baseline. Secondary: To assess the safety and tolerability of oxaliplatin To assess time to progression and…
- Trial name
- NCT00782041
- Testing
- Oxaliplatin, 5-FluoroUracil, Folinic acid
- Where
- Thailand
- Volunteers
- 11 people
- Sponsor
- Sanofi
Nasopharyngeal Carcinoma
Reduced Target Delineation and Radiation Doses Chemoradiotherapy for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
To determine the efficacy and safety of sequential chemoradiotherapy with regimen of docetaxel, cisplatin and fluorouracil and reduced target delineation and radiation doses IMRT for patients with locoregionally advanced…
- Trial name
- NCT03389295
- Testing
- Reduced Target Delineation and Radiation Doses
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Xiayun He, MD
Colorectal Cancer Metastatic, mCRC
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
QUILT 3.071 NANT Colorectal Cancer (CRC) Vaccine: This is a Phase 1b/2 study investigating the effect of NANT CRC vaccine vs regorafenib in subjects with CRC who were previously treated with SOC.
- Trial name
- NCT03563157
- Testing
- Aldoxorubicin Hydrochloride, ALT-803, ETBX-011
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- ImmunityBio, Inc.
Gastric Cancer
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced…
- Trial name
- NCT05702229
- Testing
- Rilvegostomig, Volrustomig, FOLFOX
- Where
- 44 sites in United States, China and 5 more
- Volunteers
- 163 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.